Erianin mitigates diabetic cardiomyopathy via adenosine monophosphate-activated protein kinase-nuclear factor erythroid 2-related factor 2-heme oxygenase-1 pathway activation

Figure 10  Inhibition of nuclear factor erythroid 2-related factor 2 reverses the effect of erianin on the expression of the nuclear factor erythroid 2-related factor 2 signaling pathway in myocardial tissue of mice with type 2 diabetes mellitus. A: Western blot analysis of phosphorylated adenosine monophosphate-activated protein kinase (pAMPK), adenosine monophosphate-activated protein kinase, heme oxygenase-1 (HO-1), and NAD(P)H:quinone oxidoreductase 1 (NQO1) in type 2 diabetes mellitus mice; B: pAMPK protein levels; C: HO-1 protein levels; D: NQO1 protein levels. Bar charts represent the mean ± SEM, n = 8. ^cP < 0.001 vs control group; ^fP < 0.001 vs model group; AMPK: Adenosine monophosphate-activated protein kinase; pAMPK: Phosphorylated adenosine monophosphate-activated protein kinase; Nrf2: Nuclear factor erythroid 2-related factor 2; HO-1: Heme oxygenase-1; NQO1: NAD(P)H:quinone oxidoreductase 1; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase.